Carlisle Companies (CSL) Upgraded to Market Perform at FBR Capital

Carlisle Companies (CSL) has been upgraded today by the securities research analysts at investment firm FBR Capital which upgraded Carlisle from a “under perform” rating to “market perform.”  FBR Capital also raised their performance outlook for CSL and adjusted their price target from $35 to $45 dollars.  FBR noted that their rating change is based on Carlisle’s impressive accretion after their recent acquisition of Hawk.  Additionally, company fiscal year 2011 & 2012 estimates are moved in-line with consensus.

After stumbling into 2011 there has been nothing but upside to shares of CSL.  Overall positive sentiment underlies CSL as it keeps setting higher high one after another, coupled with higher lows.  Noteworthy, however, is CSL’s recent stint of consolidation which begins with the standing 52-week high of $50.60 which a run was made on during a bullish drive in June.  CSL has been under a pullback since then, though.

Carlisle is slated to release their next earnings report on July 26th, 2011, and the current consensus EPS estimate is expected to be 91 cents.  Their last earnings report was released on April 26th, 2011, and announced EPS of 37 cents with revenue totaling $693.6 million which was up 26.7% year to year.  CSL is currently trading between its 50 & 200-day moving averages and 2011 is an up  year for the company.

Carlisle is a diversified manufacturing company consisting of five segments which manufacture and distribute a broad range of products.  The company has market capitalization of $2,873,244,340 and 61,211,000 shares outstanding.  CSL has a 52-week high of $50.60 with the low being $27.97 dollars.

Latest News

Recro Pharma Inc  Expected to Post Earnings of -$0.75 Per Share
Recro Pharma Inc Expected to Post Earnings of -$0.75 Per Share
Analysts Anticipate Paylocity Holding Corp  to Announce $0.24 Earnings Per Share
Analysts Anticipate Paylocity Holding Corp to Announce $0.24 Earnings Per Share
La Jolla Pharmaceutical  Expected to Announce Quarterly Sales of $7.12 Million
La Jolla Pharmaceutical Expected to Announce Quarterly Sales of $7.12 Million
Webcoin Market Cap Tops $168,665.00
Webcoin Market Cap Tops $168,665.00
StockChain 24-Hour Trading Volume Reaches $73,685.00
StockChain 24-Hour Trading Volume Reaches $73,685.00
$2.03 EPS Expected for DXC Technology Co  This Quarter
$2.03 EPS Expected for DXC Technology Co This Quarter


© 2006-2018 Ticker Report